Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
GlaxoSmithKline will exit the rare-disease field by transferring its business to Orchard Therapeutics. In exchange, GSK will get a 19.9% stake in Orchard. The portfolio being transferred includes Strimvelis, a gene therapy approved in Europe in 2016 to treat children with a rare immunodeficiency. GSK announced plans to exit the field last year as part of a narrowing of its R&D focus.
This article has been sent to the following recipient: